Inhibition of HIV-1 infectivity through an innate mechanism involving naturally occurring IgM anti-leukocyte autoantibodies

Journal of Immunology

Volumn 180, Issue 3, 2008, Pages 1769-1779

  Lobo, Peter I ^a,b   Schlegel, Kailo H ^a   Yuan, Wen ^a,b   Townsend, Gregory C ^a   White, Jennifer A ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CD3 ANTIGEN; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; EPITOPE; IMMUNOGLOBULIN M; LEUKOCYTE ANTIBODY; VACCINE; CHEMOKINE RECEPTOR CXCR4; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ARTICLE; CELL LINE; ERYTHROCYTE GHOST; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; INNATE IMMUNITY; PRIORITY JOURNAL; VIRUS ATTACHMENT; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS STRAIN; ANIMAL; CHRONIC KIDNEY FAILURE; DISEASE MODEL; DRUG EFFECT; GIANT CELL; IMMUNOLOGY; ISOLATION AND PURIFICATION; LEUKOCYTE; MOUSE; MOUSE MUTANT; PATHOGENICITY; PHYSIOLOGY; VIRUS ENTRY;

ANIMALS; ANTIGENS, CD4; AUTOANTIBODIES; DISEASE MODELS, ANIMAL; GIANT CELLS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, NATURAL; IMMUNOGLOBULIN M; KIDNEY FAILURE, CHRONIC; LEUKOCYTES; MICE; MICE, SCID; RECEPTORS, CXCR4; VIRUS INTERNALIZATION;

EID: 40749133411     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.3.1769     Document Type: Article

References (46)

1. Lobo, P. I., K. H. Schlegel, A. Park, C. E. Spencer, C. Chisholm, C. Christ, N. Mchedlishvili, and C. Burtner. 2007. Naturally occurring IgM anti-leukocyte autoantibodies (IgM-ALA) inhibit T cell activation and chemotaxis. J. Immunol. 180: 1780-1791.
2. Daniel, V., R. Weimer, K. Schimpf, and G. Opelz. 1989. Autoantibodies against CD4 and CD8 positive T-lymphocytes in HIV infected hemophilia patients. Vox Sang. 57: 172-176.
3. Dorsett, B., W. Cronin, V. Chuma, and H. I. Iochim. 1985. Anti-lymphocyte antibodies in patients with the acquired immune deficiency syndrome. Am. J. Med. 78: 621-626.
4. Griggi, T., R. Bauer, T. Garofalo, S. Kukel, L. Lenti, A. P. Massetti, C. Muller, M. Sorice, and G. M. Pointieri. 1994. Autoantibodies against ganglioside GM3 represents a portion of antilyphocytic antibodies in AIDS patients. Scand. J. Immunol. 40: 77-82.
5. Strickler, R. B., T. M. McHugh, D. J. Moody, W. J. W. Morrow, D. P. Stites, M. A. Shuman, and J. A. Levy. 1987. An AIDS-related cytotoxic autoantibody reacts with a specific antigen on stimulated CD4 cells. Nature 327: 710-713.
6. Williams, R. C., H. Masur, and T. J. Spira. 1984. Lymphocyte reactive antibodies in acquired immune deficiency syndrome. J. Clin. Immunol. 4: 118-123.
7. Stimmler, M. M., F. P. J. Quismorio, W. G. McGehee, T. Boylen, and O. P. Sharma. 1989. Anticardiolipin antibodies in acquired immunodeficiency syndrome. Arch. Intern. Med. 149: 1833-1835.
8. Warren, R. Q., E. A. Johnson, R. P. Donnelly, M. F. Lavia, and K. Y. Tsang. 1988. Specificity of anti-lymphocyte antibodies in sera from patients with AIDS-related complex (ARC) and healthy homosexuals. Clin. Exp. Immunol. 73: 168-173.
9. Chabot, D. J., H. Chen, D. S. Dimitrov, and C. C. Broder. 2000. N-linked glycosylation of CXCR4 masks coreceptor function for CCR5-dependent human immunodeficiency virus type 1 isolates. J. Virol. 74: 4404-4413.
10. Yang, X., R. Wyatt, and J. Sodroski. 2001. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J. Virol. 75: 1165-1171.
11. Torbett, B. E., G. Picchio, and D. E. Mosier. 1991. Hu-PBL-SCID mice: a model for human immune function, AIDS, and lymphoma genesis. Immunol. Rev. 124: 139-164.
12. Wu, L. G. LaRosa, N. Kassam, C. J. Gordon, H. Heath, N. Ruffing, H. Chen, J. Humblias, M. Sampson, M. Parmentier, et al. 1997. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and single domain for chemokine binding. J. Exp. Med. 186: 1373-1381.
13. Power, C. A., S. S. Sutterwalla, R. W. Doms, N. R. Landau, and J. A. Hoxie. 1996. CD4 independent infection by HIV-2 is mediated by fusin/CXCR4. Cell 87: 745-756.
14. Bariband, F., T. G. Edwards, M. Sharron, A. Brelot, N. Heveker, K. Price, F. Mortari, M. Alizon, M. Isang, and R. W. Doms. 2001. Antigenically distinct conformations of CXCR4. J. Virol. 75: 8957-8967.
15. Daar, E. S., X. L. Li, T. Moudgil, and D. D. Ho. 1990. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc. Natl. Acad. Sci. USA 87: 6574-6578.
16. Trkola, A. H., P. Kuster, B. Rusert, M. Joos, C. Fischer, A. Leemann, M. Manrique, M. Huber, A. Rehr, R. Oxenius, et al. 2005. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11: 615-622.
17. Prince, A., B. Horowitz, L. Baker, R. W. Shulman, H. Ralph, J. Valinsky, A. Cundell, B. Brotman, W. Boehle, and F. Rey. 1988. Failure of a human immunodeficiency virus (HIV) immune globulin to protect chimpanzees against experimental challenge with HIV. Proc. Natl. Acad. Sci. USA 85: 6944-6948.
18. Bonapur, B., J. Sernatinger, and J. A. Levy. 1986. The AIDS associated retrovirus is not sensitive to lysis or inactivation by human sera. Virology 152: 268-271.
19. Hoshino, H., H. Tanaka, M. Mina, and H. Okador,. 1984. Human T-cell leukaemia virus is not lysed by human serum. Nature 310: 324-325.
20. Rodman, T. C., J. D. Lutton, S. Jiang, H. B. Kouatly, and R. Winston. 2001. Circulating natural IgM antibodies and their corresponding human cord blood cell-derived Mabs specifically combat the Tat protein of HIV. Exp. Hematol. 29: 1004-1009.
21. Llorente, M., S. Sanchez-Palomino, S. Manes, P. Lucas, L. Kremer, I. M. DeAlborne, J. L. Toran, J. Alcami, G. DelReal, and A. C. Martinez. 1999. Natural human antibodies retrieved by phage display libraries from healthy donors: polyreactivity and recognition of HIV-1 gp 120 epitopes. Scand. J. Immunol. 50: 270-279.
22. Moore, J. P., A. McKeating, Y. Huang, A. Ashkenazi, and D. D. Ho. 1992. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD-4 (sCD-4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD-4 sensitive isolates. J. Virol. 66: 235-243.
23. Vittecoq, D. S. Chevret, L. Morand-Joubert, F. Heshamat, F. Audit, M. Bary, J. Dusaitor, A. Bismuth, J. P. Viard, F. Barre-Sinousi, et al. 1995. Passive immunotherapy in AIDS: a double blind randomized study based on transfusions of plasma rich in anti-HIV-1 antibodies versus transfusions of seronegative plasma. Proc. Natl. Acad. Sci. USA 92: 1195-1199.
24. Karpas, A., I. K. Hewlett, F. Hill, J. Gray, N. Byron, D. Gilgen, V. Bally, J. K. Oates B. Gazzard, and J. E. Epstein. 1990. Polymerase chain reaction evidence for HIV-1 neutralization by passive immunization in patients with AIDS and AIDS related complex. Proc. Natl. Acad. Sci. USA 87: 7613-7617.
25. Levy, J., T. Youvan, and M. L. Lee. 1994. Passive hyperimmune therapy in the treatment of AIDS: results of a multi center double blind controlled trial. Blood 84: 2130-2135.
26. Schooley, R. T., T. C. Merigan, M. S. Hirsch, M. S. Holodnly, M. Flynn, T. Liu, S. Byington, R. E. Henochowicz, and S. Gubish. 1990. Recombinant soluble CD-4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex: a phase I-II escalating dosage trial. Ann. Intern. Med. 112: 241-242.
27. Bouhlal, H., H. Hocini, C. Quillent-Gregoire, V. Donkova, S. Rose, A. Amara, R. Longhi, N. Haeffner-Cavaillon, A. Beretta, S.V. Kaveri, and M. D. Kazatchkine. 2001. Antibodies to C-C chemokine receptor 5 in normal human IgG block infection of macrophages and lymphocytes with primary R5-tropic strains of HIV-1. J. Immunol. 166: 7606-7611.
28. Ditzel, H. J., M. M. Rosenkilde, P. Garred, M. Wang, K. Koefoed, C. Pedersen, D. R. Burton, and T. W. Schwartz. 1998. The CCR5 receptor acts as an alloantigen in CCR5 δ32 homozygous individuals: identification of chemokine and HIV-1-blocking human antibodies. Proc. Natl. Acad. Sci. USA 95: 5241-5245.
29. Lopalco, L., C. Barassi, C. Pastori, R. Longhi, R. S. E. Burastero, G. Tambussi, F. Mazzotta, A. Lazzarin, M. Clerici, and A. G. Siccardi. 2000. CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 In vitro. J. Immunol. 164: 3426-3433.
30. Lehner, T., Y. Wang, C. Doyle, L. Tao, L. A. Bergmeier, E. Mitchell, W. M. Bogers, J. Heeney, C. G. Kelly, and T. Lehner. 1999. Induction of inhibitory antibodies to the CCR5 chemokine receptor and their complementary role in preventing SIV infection in macaques. Eur. J. Immunol. 29: 2427-2435.
31. Burastero, S. E., D. Gafffi, L. Lopalco, G. Tambussi, B. Borgonovo, C. De Santis, C. Abecasis, P. Robbioni, A. Gasparri, A. Lazzarin, et al. 1996. Autoantibodies to CD4 in HIV type 1-exposed seronegative individuals. AIDS Res. Hum. Retroviruses 12: 273-280.
32. Navin, T., E. Krug, and R. Pearson. 1989. Effect of IgM from normal human serum on Leishmania donovani promastigote agglutination, complement mediated killing, and phagocytosis by human monocytes. Infect. Immunol. 57: 1343-1349.
33. Ochsenbein, A. F., T. Fehr, C. Lutz, M. Suter, F. Brombacher, H. Hengartner, and R. M. Zinkernagel. 1999. Control of early viral and bacterial distribution and disease by natural antibodies. Science 286: 2156-2159.
34. Baumgarth, N., O. C. Herman, G. C. Jager, L. E. Brown, L. A. Herzenberg, J. Chen. 2000. B-1 and B-2 cell derived immunoglobulin M antibodies are non-redundant componants of the protective response to influenza virus infection. J. Exp. Med. 192: 271-280.
35. Kinter, A., J. Arthos, C. Cicala, and A. S. Fauci. 2000. Chemokines, cytokines, and HIV: a complex network of interactions that influence HIV pathogenesis. Immunol. Rev. 177: 88-98.
36. Deeks, S. G., and B. D. Walker. 2004. The immune response to AIDS virus infection: good, bad, or both? J. Clin. Invest. 113: 808-810.
37. + T cells in control of SIV replication. J. Clin. Invest. 113: 836-845.
38. Rizzardi, G. P., A. Harari, B. Capiluppi, G. Tambussi, K. Ellefsen, D. Ciuffreda, P. Champagne, P. A. Bart, J. P. Chave, A. Lazzarin, and G. Pantaleo. 2002. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J. Clin. Invest. 109: 681-688.
39. Belanger, F., L. Meyer, N. Carre, A. Coutellier, and C. Deveau. 1997. Influence of age at infection on human immunodeficiency virus disease progression to different clinical endpoints: the SEROCO cohort (1988-1994): the seroco study group. Int. J. Epidemiol. 26: 1340-1345.
40. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. 2000. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis: concerted action on SeroConversion to AIDS and death in Europe. Lancet 1355: 1131-1137.
41. Fritsch, L., V. Marechal, V. Schneider, C. Barthet, W. Rozenbaum, M. Moisan-Coppey, J. Coppey, and J. C. Nicolas. 1998. Production of HIV-1 by human B cells infected in vitro: characterization of an EBV genome-negative B cell line chronically synthesizing a low level of HIV-1 after infection. Virology 244: 542-551.
42. Moir, S., R. Lapointe, A. Malaspina, M. Ostrowski, C. E. Cole, T. W. Chun, J. Adelsberger, M. Baseler, P. Hwu, and A. S. Fauci. 1999. CD40-mediated induction of CD4 and CXCR4 on B lymphocytes correlates with restricted susceptibility to human immunodeficiency virus type 1 infection: potential role of B lymphocytes as a viral reservoir. J. Virol. 73: 7972-7980.
43. Townsley-Fuchs, J., M. S. Neshat, D. H. Margolin, J. Braun, and L. Goodglick. 1997. HIV-1 gp120-a novel viral B cell superantigen. Int. Rev. Immunol. 14: 325-338.
44. + B cells. J. Clin. Invest. 99: 2488-2501.
45. L segments of polyreactive and monoreactive human natural antibodies to HIV-1 and E. coli β-galactosidase. Int. Immunol. 5: 1523-1533.
46. Rodman, T. C., F. H. Pruslin, S. E. To, and R. Winston. 1992. HIV-1 Tat-reactive antibodies present in normal HIV-1 negative sera and depleted in HIV-1 positive sera. J. Exp. Med. 175: 1247-1253.